Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader
Axsome Therapeutics reported FDA approval of AUVELITY (dextromethorphan HBr and bupropion HCl) for treating agitation associated with dementia due to Alzheimer’s disease. The approval marks AUVELITY as a first-in-class treatment targeting specific brain receptors and expands its use beyond major depressive disorder. The company hosted an investor e…